Literature DB >> 23117948

Inclusion body myositis.

Mazen M Dimachkie1, Richard J Barohn.   

Abstract

The idiopathic inflammatory myopathies are a group of rare disorders that share many similarities. These include dermatomyositis (DM), polymyositis (PM), necrotizing myopathy (NM), and sporadic inclusion body myositis (IBM). Inclusion body myositis is the most common idiopathic inflammatory myopathy after age 50 and it presents with chronic proximal leg and distal arm asymmetric mucle weakness. Despite similarities with PM, it is likely that IBM is primarily a degenerative disorder rather than an inflammatory muscle disease. Inclusion body myositis is associated with a modest degree of creatine kinase (CK) elevation and an abnormal electromyogram demonstrating an irritative myopathy with some chronicity. The muscle histopathology demonstrates inflammatory exudates surrounding and invading nonnecrotic muscle fibers often times accompanied by rimmed vacuoles. In this chapter, we review sporadic IBM. We also examine past, essentially negative, clinical trials in IBM and review ongoing clinical trials. For further details on DM, PM, and NM, the reader is referred to the idiopathic inflammatory myopathies chapter. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2012        PMID: 23117948      PMCID: PMC3535450          DOI: 10.1055/s-0032-1329197

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  51 in total

1.  Inclusion Body Myositis.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-01       Impact factor: 3.598

2.  Myeloid dendritic cells in inclusion-body myositis and polymyositis.

Authors:  Steven A Greenberg; Geraldine S Pinkus; Anthony A Amato; Jack L Pinkus
Journal:  Muscle Nerve       Date:  2007-01       Impact factor: 3.217

Review 3.  Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition.

Authors:  Valerie Askanas; W King Engel
Journal:  Neurology       Date:  2006-01-24       Impact factor: 9.910

4.  A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities.

Authors:  Fieke M Cox; Maarten J Titulaer; Jacob K Sont; Axel R Wintzen; Jan J G M Verschuuren; Umesh A Badrising
Journal:  Brain       Date:  2011-09-09       Impact factor: 13.501

5.  Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients.

Authors:  Umesh A Badrising; Marion L C Maat-Schieman; Johannes C van Houwelingen; Peter A van Doorn; Sjoerd G van Duinen; Baziel G M van Engelen; Carin G Faber; Jessica E Hoogendijk; Aeiko E de Jager; Peter J Koehler; Marianne de Visser; Jan J G M Verschuuren; Axel R Wintzen
Journal:  J Neurol       Date:  2005-06-17       Impact factor: 4.849

6.  Long-term observational study of sporadic inclusion body myositis.

Authors:  Olivier Benveniste; Marguerite Guiguet; Jane Freebody; Odile Dubourg; Waney Squier; Thierry Maisonobe; Tanya Stojkovic; Maria Isabel Leite; Yves Allenbach; Serge Herson; Stefen Brady; Bruno Eymard; David Hilton-Jones
Journal:  Brain       Date:  2011-10-12       Impact factor: 13.501

7.  Inclusion body myositis: explanation for poor response to immunosuppressive therapy.

Authors:  R J Barohn; A A Amato; Z Sahenk; J T Kissel; J R Mendell
Journal:  Neurology       Date:  1995-07       Impact factor: 9.910

8.  Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM.

Authors:  Nizar Chahin; Andrew G Engel
Journal:  Neurology       Date:  2007-09-19       Impact factor: 9.910

Review 9.  Ischemic strength training: a low-load alternative to heavy resistance exercise?

Authors:  M Wernbom; J Augustsson; T Raastad
Journal:  Scand J Med Sci Sports       Date:  2008-05-03       Impact factor: 4.221

10.  Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases.

Authors:  M Needham; I James; A Corbett; T Day; F Christiansen; B Phillips; F L Mastaglia
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-02-07       Impact factor: 10.154

View more
  15 in total

Review 1.  A rare association of early-onset inclusion body myositis, rheumatoid arthritis and autoimmune thyroiditis: a case report and literature review.

Authors:  A M Clerici; G Bono; M L Delodovici; G Azan; G Cafasso; G Micieli
Journal:  Funct Neurol       Date:  2013 Apr-May

2.  Immunohistochemical and ultrastructural analysis of sporadic inclusion body myositis: a case series.

Authors:  Katarzyna Haczkiewicz; Agata Sebastian; Aleksandra Piotrowska; Maria Misterska-Skóra; Agnieszka Hałoń; Marta Skoczyńska; Maciej Sebastian; Piotr Wiland; Piotr Dzięgiel; Marzenna Podhorska-Okołów
Journal:  Rheumatol Int       Date:  2018-12-08       Impact factor: 2.631

3.  Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes.

Authors:  Jerry R Mendell; Zarife Sahenk; Samiah Al-Zaidy; Louise R Rodino-Klapac; Linda P Lowes; Lindsay N Alfano; Katherine Berry; Natalie Miller; Mehmet Yalvac; Igor Dvorchik; Melissa Moore-Clingenpeel; Kevin M Flanigan; Kathleen Church; Kim Shontz; Choumpree Curry; Sarah Lewis; Markus McColly; Mark J Hogan; Brian K Kaspar
Journal:  Mol Ther       Date:  2017-03-06       Impact factor: 11.454

4.  Clinicopathological features of sarcoidosis manifesting as generalized chronic myopathy.

Authors:  Shinya Maeshima; Haruki Koike; Seiya Noda; Tomoko Noda; Hirotaka Nakanishi; Masahiro Iijima; Mizuki Ito; Seigo Kimura; Gen Sobue
Journal:  J Neurol       Date:  2015-02-26       Impact factor: 4.849

5.  Asymptomatic hyper-creatine-kinase-emia as sole manifestation of inclusion body myositis.

Authors:  Josef Finsterer; Claudia Stöllberger; Gabor G Kovacs
Journal:  Neurol Int       Date:  2013-06-25

6.  Development and evaluation of a standardized ELISA for the determination of autoantibodies against cN-1A (Mup44, NT5C1A) in sporadic inclusion body myositis.

Authors:  Sabine L Kramp; Dmitry Karayev; Guo Shen; Allan L Metzger; Robert I Morris; Eugene Karayev; Yvonne Lam; Richard M Kazdan; Ger J M Pruijn; Sandra Saschenbrecker; Cornelia Dähnrich; Wolfgang Schlumberger
Journal:  Auto Immun Highlights       Date:  2016-11-17

7.  Mortality and Causes of Death in Patients with Sporadic Inclusion Body Myositis: Survey Study Based on the Clinical Experience of Specialists in Australia, Europe and the USA.

Authors:  Mark A Price; Victoria Barghout; Olivier Benveniste; Lisa Christopher-Stine; Alastair Corbett; Marianne de Visser; David Hilton-Jones; John T Kissel; Thomas E Lloyd; Ingrid E Lundberg; Francis Mastaglia; Tahseen Mozaffar; Merrilee Needham; Jens Schmidt; Kumaraswamy Sivakumar; Carla DeMuro; Brian S Tseng
Journal:  J Neuromuscul Dis       Date:  2016-03-03

8.  Inclusion Body Myositis: A Case Presenting with Respiratory Failure and Autopsy Findings Leading to the Hypothesis of a Paraneoplastic Cause.

Authors:  Christopher Dardis; Ariel Antezana; Kurenai Tanji; Paul J Maccabee
Journal:  Am J Case Rep       Date:  2017-06-23

9.  Late-onset neuromuscular disorders in the differential diagnosis of sarcopenia.

Authors:  Fabian Hofmeister; Lisa Baber; Uta Ferrari; Stefan Hintze; Stefanie Jarmusch; Sabine Krause; Peter Meinke; Stefan Mehaffey; Carl Neuerburg; Fabiana Tangenelli; Benedikt Schoser; Michael Drey
Journal:  BMC Neurol       Date:  2021-06-25       Impact factor: 2.474

Review 10.  What Every Neuropathologist Needs to Know: The Muscle Biopsy.

Authors:  James S Nix; Steven A Moore
Journal:  J Neuropathol Exp Neurol       Date:  2020-07-01       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.